When developing an early market access strategy, companies must remember: • To engage with payers at the earliest…
You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
Expert in outcomes and evidence, Richard Willke, talks through early-stage economic modeling using pharmacokinetic/ pharmacodynamic (PK/PD) data sets; detailing what has been achieved so far and what further potential it holds.
However promising a product might appear, if you do not have the right evidence early on (or if you fail to recognize…
Early Planning & Modelling
Pricing & Reimbursement